ACI HealthCare Limited (AHL)’s mission is to achieve business excellence through quality by planning, implementing, controlling and improving the standards of its products & services for exceeding customer expectations on continuous basis.

ACI HealthCare Limited (AHL)’s vision is to play a leading role in improving the quality of life and well-being of the people through responsible application of knowledge and skills.

• Quality:
  We maintain uncompromising standards in every step of development, manufacturing, and release — ensuring patient safety and product reliability.
• Customer Focus:
  We listen, understand, and respond to the needs of healthcare systems, partners, prescribers, and patients to deliver meaningful value.
• Innovation:
  We encourage scientific thinking, practical improvements, and technology adoption that enhance performance, efficiency, and healthcare outcomes.
• Fairness:
  We act with integrity, equity, and responsibility — building trust across all stakeholders, internally and externally.
• Transparency:
  We believe in open, honest communication and traceable decision-making, reinforcing accountability and regulatory confidence.
• Continuous Improvement:
  We challenge ourselves to do better every day — learning from outcomes, optimizing processes, and proactively raising our performance benchmark.

ACI HealthCare Limited is structured to operate within regulated and quality-driven global markets, with established and expanding engagement across the United States, Europe, the Middle East and North Africa, Asia Pacific, and Latin America. Our operating model emphasizes regulatory alignment, reliable supply performance, and lifecycle quality governance, enabling sustainable participation in diverse international healthcare systems. Looking ahead, our strategic growth priorities include biosimilars, select API backward integration, and advanced delivery and control-release platforms — strengthening our capability to support complex, high-value, and globally relevant therapeutic solutions.

At ACI HealthCare Limited, quality is the foundation of every decision, process, and product. Our Quality Management System is aligned with global cGMP standards, international regulatory expectations, and industry best practices to ensure safety, consistency, and reliability across all operations. We continuously strengthen our systems through structured planning, monitoring, and improvement, ensuring that we not only meet but exceed stakeholder and patient expectations. Our people are trained, empowered, and accountable for upholding quality at every stage — reflecting our belief that quality is not an act, but a culture.

Data Integrity is a core principle of our pharmaceutical quality system. ACI HealthCare ensures that all data — whether electronic or paper — is managed according to the ALCOA+ principles: attributable, legible, contemporaneous, original, accurate, complete, consistent, and enduring. We maintain secure, controlled systems and train all employees to understand, protect, and uphold data integrity throughout the data lifecycle. We encourage transparency and reporting of any concerns without hesitation, reinforcing a culture where trust, traceability, and scientific credibility are non-negotiable.

Our manufacturing platform is built to support consistent, complaint, and scalable production for regulated international markets. All operations are executed within controlled environments, governed by validated procedures, and monitored through digital traceability and documentation systems that ensure end-to-end reliability from development through commercialization.
Key Attributes:

• Integrated production workflows with structured material handling, environmental controls, and validated cleaning and changeover practices.
• Data-governed batch execution ensuring complete traceability, audit readiness, and lifecycle documentation integrity.
• GMP-aligned facility and utility systems, including classified HVAC zoning, purified utilities, automated controls, and real-time monitoring.
• Continuous improvement mindset driving process robustness, deviation prevention, and sustainable operational performance aligned with regulatory expectations.

Our Quality System is structured according to the ICH Pharmaceutical Quality System (PQS) model, where product and process understanding, quality risk management, and knowledge management work together as an integrated lifecycle framework. Quality is not an endpoint — it is designed, maintained, and continually improved through deliberate scientific and operational control strategies.
What Defines Our Approach:

• ICH Q10-Based PQS Architecture
  A lifecycle governance model linking development, technology transfer, commercial manufacturing, and post-market monitoring.
• Science & Risk-Based Quality (ICH Q8/Q9)
  Product and process decisions based on critical quality attributes (CQA), critical process parameters (CPP), and structured risk assessments.
• Continuous Improvement via PDCA
  A systematic Plan–Do–Check–Act cycle embedded across operations to enhance robustness, reduce variability, and prevent recurrence of issues.
• CAPA Effectiveness & Knowledge Management
  Issues are evaluated at their root cause, and improvements are captured, institutionalized, and fed back into operational learning, strengthening reliability over time.
• Digital & Data-Driven Oversight
  Batch history, trend analysis, stability insights, and deviation intelligence support real-time, evidence-based decision making.

Our Research & Development function operates on a science-based, data-driven development framework guided by the principles of ICH Q8 (Pharmaceutical Development), ICH Q9 (Quality Risk Management), and integrated lifecycle governance aligned with ICH Q10 (Pharmaceutical Quality System). We build product and process understanding from the earliest development phase, ensuring that performance, manufacturability, and patient use requirements are addressed proactively.

R&D activities are structured across Formulation Development, Analytical Development, Packaging and Labelling Development, and R&D Quality Assurance, working as a unified platform supported by Quality by Design (QbD), risk evaluation, and knowledge management. Development decisions are informed through structured experimentation, trend interpretation, process capability assessment, and stability performance insights — enabling robust scale-up and efficient technology transfer into commercial manufacturing.

Core R&D Practices Include:

• QbD-enabled formulation and process understanding
• Risk assessment and mitigation throughout the development lifecycle
• Analytical method development and lifecycle management
• Material and component qualification based on performance and compatibility
• Technology transfer supported by documented process knowledge
• Stability evaluation driven by ICH climatic zone requirements This approach ensures that products entering commercialization have clear process control strategies, defined critical parameters, and evidence-based performance reliability — supporting long-term supply assurance and global regulatory acceptance.

This approach ensures that products entering commercialization have clear process control strategies, defined critical parameters, and evidence-based performance reliability — supporting long-term supply assurance and global regulatory acceptance.

Our product strategy is centered on high-quality, reliable generic medicines that support accessible and sustainable healthcare. Generics play a vital role in treatment affordability worldwide, ensuring that patients and healthcare systems can benefit from proven therapies without compromising quality. At ACI HealthCare Limited, we develop generics with a science-based, risk-managed, and lifecycle-controlled approach, ensuring consistent performance and regulatory confidence across the markets we serve. Our development pipeline focuses on therapeutically relevant and clinically established medicines where access, supply security, and cost efficiency have the greatest impact. We apply Quality by Design (QbD) principles, structured stability programs, and knowledge-driven scale-up to ensure that every product is robust, safe, and globally acceptable. As we expand our international footprint, our portfolio approach prioritizes value-driven generics today, while building capability toward complex generics, controlled-release platforms, and selective future biosimilar pathways. Strategic Direction

• Current Focus: High-quality generics for regulated global markets and enhanced technology-enabled formulations and controlled-release platforms
• Long-Term Development Pathway: Biosimilars and API backward integration to strengthen sustainability and resilience

ACI HealthCare Limited partners with pharmaceutical companies seeking a reliable, compliant, and quality-driven manufacturing platform for regulated international markets. Our operating model emphasizes technical transparency, lifecycle documentation control, and disciplined quality governance, ensuring that every product manufactured under partnership adheres to agreed specifications, regulatory expectations, and performance standards.
We support partners from technology transfer through commercial production, applying structured project management, knowledge transfer frameworks, and risk-based process verification. Our focus is on building long-term, trust-based relationships where efficiency, quality, and supply reliability are continually strengthened through collaboration.
Partnership Strengths:

• Structured Technology Transfer supported by documented process and analytical knowledge
• Lifecycle Quality Oversight from development through commercial release
• Data Integrity and Traceability for full audit confidence
• Flexible, transparent communication and joint decision pathways
• Commitment to sustainable and dependable supply performance

We approach sustainability as an essential part of how we operate — not an initiative, but a duty. ACI HealthCare Limited works to ensure that our decisions support the health of people, the strength of communities, and the protection of the environment. We integrate sustainable thinking into manufacturing practices, supply chain selection, resource utilization, and workforce development to create value that is ethical, responsible, and enduring.
Our priorities include responsible manufacturing, minimizing environmental impact through efficient resource and waste management, and maintaining an ethical and traceable supply chain. We foster a safe, inclusive, and supportive workplace where people are respected, empowered, and encouraged to grow.